The US Food and Drug Administration today approved Evrysdi (risdiplam) to treat patients two months of age and older with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement. This is the first oral drug approved to treat this disease.
Evrysdi the first at-home, orally administered treatment for spinal muscular atrophy (SMA) in adults and children 2 months and older, said PTC Therapeutics (Nasdaq: PTCT), which developed the drug as part of a collaboration with Swiss pharma giant Roche (ROG: SIX) and the SMA Foundation, and saw its shares gain 1.7% to $47.83 on Friday. The FDA granted this approval of Evrysdi to Roche subsidiary Genentech.
“Evrysdi is the first drug for this disease that can be taken orally, providing an important treatment option for patients with SMA, following the approval of the first treatment for this devastating disease less than four years ago,” said Dr Billy director of the Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze